Rapport Therapeutics (RAPP) stock: insider trades, news & valuation
Heavy selling
Close · Oct 9, 2026
$30.65
+2.7% on the day
+14.6% over 12 months
52-week range $24.37 – $52.50
Share price and insider trades
RAPP closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$47.7M
Insiders buying0
Insiders selling6
Rapport Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 6 sold $47.7M of RAPP stock on the open market.
Get emailed when insiders cluster-buy stocks like RAPP
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
RAPP insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $143K | 2 |
| Q3 2026 | — | 0 | $7.1M | 21 |
| Q2 2026 | — | 0 | $36.7M | 16 |
| Q1 2026 | — | 0 | $1.7M | 15 |
| Q4 2025 | — | 0 | $2.0M | 23 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day0.7×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 Rapport Therapeutics, Inc. insiders reported open-market purchases totaling $0, while 6 insiders reported sales totaling $47.7M. 74 of 77 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 8SEC | Abraham CeesayCEO | Sell Plan | 3,375453,392 held (−1%) | $32.03 | $108K | -4.3% | — |
| Oct 8SEC | Abraham CeesayCEO | Sell Plan | 1,147452,245 held (−0%) | $30.66 | $35K | -0.0% | — |
| Oct 1SEC | Cheryl GaultCOO | Sell Plan | 7,925141,989 held (−5%) | $33.04 | $262K | -7.2% | — |
| Oct 1SEC | Cheryl GaultCOO | Sell Plan | 2,075139,914 held (−1%) | $33.76 | $70K | -9.2% | — |
| Sep 24SEC | Abraham CeesayCEO | Sell Plan | 1,952457,025 held (−0%) | $39.05 | $76K | -21.5% | — |
| Sep 24SEC | Abraham CeesayCEO | Sell Plan | 215456,810 held (−0%) | $39.86 | $9K | -23.1% | — |
| Sep 24SEC | Abraham CeesayCEO | Sell Plan | 43456,767 held (−0%) | $41.05 | $2K | -25.3% | — |
| Sep 9SEC | Abraham CeesayCEO | Sell Plan | 7,141460,046 held (−2%) | $45.56 | $325K | -32.7% | — |
| Sep 9SEC | Abraham CeesayCEO | Sell Plan | 1,069458,977 held (−0%) | $46.01 | $49K | -33.4% | — |
| Aug 26SEC | Krishnaswamy YeleswaramChief Development Officer | Sell Plan | 20,799212,063 held (−9%) | $50.31 | $1.0M | -39.1% | — |
| Aug 26SEC | Abraham CeesayCEO | Sell Plan | 18,921467,187 held (−4%) | $49.57 | $938K | -38.2% | — |
| Aug 26SEC | Krishnaswamy YeleswaramChief Development Officer | Sell Plan | 16,201195,862 held (−8%) | $51.06 | $827K | -40.0% | — |
| Aug 26SEC | Krishnaswamy YeleswaramChief Development Officer | Sell Plan | 13,160232,862 held (−5%) | $50.00 | $658K | -38.7% | — |
| Aug 20SEC | Krishnaswamy YeleswaramChief Development Officer | Sell Plan | 404246,022 held (−0%) | $49.90 | $20K | -38.6% | — |
| Aug 12SEC | Abraham CeesayCEO | Sell Plan | 19,500491,902 held (−4%) | $48.04 | $937K | -36.2% | — |
| Aug 12SEC | Abraham CeesayCEO | Sell Plan | 14,171523,436 held (−3%) | $45.97 | $651K | -33.3% | — |
| Aug 12SEC | Abraham CeesayCEO | Sell Plan | 8,370515,066 held (−2%) | $46.75 | $391K | -34.4% | — |
| Aug 12SEC | Abraham CeesayCEO | Sell Plan | 5,794486,108 held (−1%) | $48.62 | $282K | -37.0% | — |
| Aug 12SEC | Abraham CeesayCEO | Sell Plan | 3,664511,402 held (−1%) | $46.90 | $172K | -34.6% | — |
| Jul 29SEC | Abraham CeesayCEO | Sell Plan | 2,203537,614 held (−0%) | $42.11 | $93K | -27.2% | — |
| Jul 29SEC | Abraham CeesayCEO | Sell Plan | 7537,607 held (−0%) | $42.74 | $299 | -28.3% | — |
| Jul 15SEC | Abraham CeesayCEO | Sell Plan | 5,481542,546 held (−1%) | $39.72 | $218K | -22.8% | — |
| Jul 15SEC | Abraham CeesayCEO | Sell Plan | 2,729539,817 held (−1%) | $40.57 | $111K | -24.5% | — |
| Jul 1SEC | Abraham CeesayCEO | Sell Plan | 7,344548,903 held (−1%) | $39.77 | $292K | -22.9% | — |
| Jul 1SEC | Cheryl GaultCOO | Sell Plan | 3,792154,222 held (−2%) | $41.39 | $157K | -25.9% | — |
| Jul 1SEC | Cheryl GaultCOO | Sell Plan | 3,308150,914 held (−2%) | $42.17 | $139K | -27.3% | — |
| Jul 1SEC | Cheryl GaultCOO | Sell Plan | 1,900158,014 held (−1%) | $40.09 | $76K | -23.5% | — |
| Jul 1SEC | Cheryl GaultCOO | Sell Plan | 1,000149,914 held (−1%) | $43.15 | $43K | -29.0% | — |
| Jul 1SEC | Abraham CeesayCEO | Sell Plan | 876548,027 held (−0%) | $40.34 | $35K | -24.0% | — |
| May 28SEC | Rock Ventures V, L.p. Third10% Owner | Sell Plan | 18,5726,280,525 held (−0%) | $40.05 | $744K | -23.5% | — |
| May 13SEC | Rock Ventures V, L.p. Third10% Owner | Sell Plan | 133,6186,299,097 held (−2%) | $40.24 | $5.4M | -23.8% | — |
| May 11SEC | Rock Ventures Vi, L.p. Third10% Owner | Sell Plan | 271,4956,437,733 held (−4%) | $40.12 | $10.9M | -23.6% | — |
| May 11SEC | Rock Ventures Vi, L.p. Third10% Owner | Sell Plan | 5,0186,432,715 held (−0%) | $40.31 | $202K | -24.0% | — |
| Apr 21SEC | Rock Ventures Vi, L.p. Third10% Owner | Sell Plan | 426,0056,709,228 held (−6%) | $40.32 | $17.2M | -24.0% | — |
| Apr 21SEC | Krishnaswamy YeleswaramChief Development Officer | Sell Plan | 20,225246,426 held (−8%) | $39.99 | $809K | -23.4% | — |
| Apr 14SEC | Krishnaswamy YeleswaramChief Development Officer | Sell Plan | 10,200266,651 held (−4%) | $35.08 | $358K | -12.6% | — |
| Apr 14SEC | Krishnaswamy YeleswaramChief Development Officer | Sell Plan | 9,165276,851 held (−3%) | $34.97 | $321K | -12.4% | — |
| Apr 14SEC | Krishnaswamy YeleswaramChief Development Officer | Sell Plan | 500286,016 held (−0%) | $34.98 | $17K | -12.4% | — |
| Apr 9SEC | Krishnaswamy YeleswaramChief Development Officer | Sell Plan | 360286,516 held (−0%) | $34.90 | $13K | -12.2% | — |
| Mar 31SEC | Cheryl GaultCOO | Sell Plan | 7,161162,753 held (−4%) | $28.04 | $201K | +9.3% | — |
| Mar 31SEC | Cheryl GaultCOO | Sell Plan | 2,839159,914 held (−2%) | $28.55 | $81K | +7.4% | — |
| Mar 26SEC | Krishnaswamy YeleswaramChief Development Officer | Sell Plan | 10,115286,876 held (−3%) | $29.99 | $303K | +2.2% | — |
| Mar 9SEC | Cheryl GaultCOO | Sell | 2,014169,914 held (−1%) | $28.93 | $58K | +5.9% | — |
| Feb 19SEC | David BredtChief Scientific Officer | Sell Plan | 5,400389,275 held (−1%) | $28.95 | $156K | +5.9% | — |
| Feb 19SEC | Abraham CeesayCEO | Sell Plan | 3,552558,528 held (−1%) | $29.05 | $103K | +5.5% | — |
| Feb 19SEC | Abraham CeesayCEO | Sell Plan | 2,98322,829 held (−12%) | $29.04 | $87K | +5.5% | — |
| Feb 19SEC | Abraham CeesayCEO | Sell Plan | 2,281556,247 held (−0%) | $29.80 | $68K | +2.9% | — |
| Feb 19SEC | David BredtChief Scientific Officer | Sell Plan | 2,200387,075 held (−1%) | $29.59 | $65K | +3.6% | — |
| Feb 19SEC | Abraham CeesayCEO | Sell Plan | 2,10020,729 held (−9%) | $29.80 | $63K | +2.9% | — |
| Feb 19SEC | David BredtChief Scientific Officer | Sell Plan | 900394,675 held (−0%) | $28.02 | $25K | +9.4% | — |
| Jan 22SEC | Abraham CeesayCEO | Sell Plan | 5,833562,080 held (−1%) | $26.12 | $152K | +17.3% | — |
| Jan 22SEC | Abraham CeesayCEO | Sell Plan | 5,08325,812 held (−16%) | $26.11 | $133K | +17.4% | — |
| Jan 16SEC | David BredtChief Scientific Officer | Sell Plan | 8,300395,775 held (−2%) | $26.83 | $223K | +14.2% | — |
| Jan 16SEC | David BredtChief Scientific Officer | Sell Plan | 200395,575 held (−0%) | $27.40 | $5K | +11.9% | — |
| Jan 5SEC | David BredtChief Scientific Officer | Sell | 6,567404,075 held (−2%) | $30.05 | $197K | +2.0% | — |
| Jan 5SEC | Krishnaswamy YeleswaramChief Development Officer | Sell | 2,840296,991 held (−1%) | $30.05 | $85K | +2.0% | — |
| Dec 18SEC | Abraham CeesayCEO | Sell Plan | 2,792568,513 held (−0%) | $30.04 | $84K | +2.0% | — |
| Dec 18SEC | Abraham CeesayCEO | Sell Plan | 2,42131,410 held (−7%) | $30.04 | $73K | +2.0% | — |
| Dec 18SEC | Abraham CeesayCEO | Sell Plan | 2,441571,305 held (−0%) | $28.84 | $70K | +6.3% | — |
| Dec 18SEC | Abraham CeesayCEO | Sell Plan | 2,14733,831 held (−6%) | $28.84 | $62K | +6.3% | — |
| Dec 18SEC | Abraham CeesayCEO | Sell Plan | 600567,913 held (−0%) | $31.04 | $19K | -1.3% | — |
| Dec 18SEC | Abraham CeesayCEO | Sell Plan | 51530,895 held (−2%) | $31.04 | $16K | -1.3% | — |
| Dec 16SEC | David BredtChief Scientific Officer | Sell Plan | 7,704393,438 held (−2%) | $29.95 | $231K | +2.3% | — |
| Dec 16SEC | David BredtChief Scientific Officer | Sell Plan | 796392,642 held (−0%) | $30.68 | $24K | -0.1% | — |
| Dec 1SEC | Cheryl GaultCOO | Sell Plan | 5,000171,928 held (−3%) | $30.10 | $150K | +1.8% | — |
| Nov 18SEC | David BredtChief Scientific Officer | Sell Plan | 5,344401,142 held (−1%) | $25.39 | $136K | +20.7% | — |
| Nov 18SEC | David BredtChief Scientific Officer | Sell Plan | 3,156406,486 held (−1%) | $24.84 | $78K | +23.4% | — |
| Nov 18SEC | Abraham CeesayCEO | Sell Plan | 3,056573,746 held (−1%) | $25.43 | $78K | +20.5% | — |
| Nov 18SEC | Abraham CeesayCEO | Sell Plan | 2,84135,978 held (−7%) | $25.44 | $72K | +20.5% | — |
| Nov 18SEC | Abraham CeesayCEO | Sell Plan | 2,777576,802 held (−0%) | $24.92 | $69K | +23.0% | — |
| Nov 18SEC | Abraham CeesayCEO | Sell Plan | 2,24238,819 held (−5%) | $24.91 | $56K | +23.0% | — |
| Oct 16SEC | David BredtChief Scientific Officer | Sell Plan | 7,418410,724 held (−2%) | $25.73 | $191K | +19.1% | — |
| Oct 16SEC | Abraham CeesayCEO | Sell Plan | 4,647580,765 held (−1%) | $25.72 | $120K | +19.2% | — |
| Oct 16SEC | Abraham CeesayCEO | Sell Plan | 4,32841,816 held (−9%) | $25.75 | $111K | +19.0% | — |
| Oct 16SEC | Abraham CeesayCEO | Sell Plan | 1,186579,579 held (−0%) | $26.14 | $31K | +17.3% | — |
| Oct 16SEC | David BredtChief Scientific Officer | Sell Plan | 1,082409,642 held (−0%) | $26.16 | $28K | +17.2% | — |
| Oct 16SEC | Abraham CeesayCEO | Sell Plan | 75541,061 held (−2%) | $26.17 | $20K | +17.1% | — |
Insiders at Rapport Therapeutics, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Rock Ventures Vi, L.p. Third10% Owner | — | $28.3M | May 11, 2026 | — |
| Abraham CeesayCEO | — | $6.2M | Oct 8, 2026 | — |
| Rock Ventures V, L.p. Third10% Owner | — | $6.1M | May 28, 2026 | — |
| Krishnaswamy YeleswaramChief Development Officer | — | $4.5M | Aug 26, 2026 | — |
| David BredtChief Scientific Officer | — | $1.4M | Feb 19, 2026 | — |
| Cheryl GaultCOO | — | $1.2M | Oct 1, 2026 | — |
RAPP stock: common questions
Are Rapport Therapeutics, Inc. insiders buying RAPP stock?
In the past 12 months, 0 insiders reported open-market purchases of RAPP worth $0.
Are Rapport Therapeutics, Inc. insiders selling RAPP stock?
6 insiders reported sales worth $47.7M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is RAPP's 52-week range?
Over the past year RAPP has traded between $24.37 and $52.50. It last closed at $30.65 on Oct 9, 2026.